RTI-336, (LS-193,309, (−)-2β-(3-(4-methylphenyl)isoxazol-5-yl)-3β-(4-chlorophenyl)tropane) is a phenyltropane derivative which acts as a potent and selective dopamine reuptake inhibitor and stimulant drug. It binds to the dopamine transporter with around 20x the affinity of cocaine,<ref>{{#invoke:Citation/CS1|citation
|CitationClass=journal
}}</ref> however it produces relatively mild stimulant effects, with a slow onset and long duration of action.<ref>{{#invoke:Citation/CS1|citation
|CitationClass=journal
}}</ref> These characteristics make it a potential candidate for treatment of cocaine addiction, as a possible substitute drug analogous to how methadone is used for treating heroin abuse.<ref>{{#invoke:Citation/CS1|citation
|CitationClass=journal
}}</ref><ref>Sofuoglu M, Kosten TR. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion on Emerging Drugs. 2006 Mar;11(1):91-98. doi:10.1517/14728214.11.1.91</ref> RTI-336 fully substitutes for cocaine in addicted monkeys and supports self-administration,<ref>{{#invoke:Citation/CS1|citation
|CitationClass=journal
}}</ref><ref>{{#invoke:Citation/CS1|citation
|CitationClass=journal
}}</ref> and significantly reduces rates of cocaine use, especially when combined with SSRIs,<ref>{{#invoke:Citation/CS1|citation
|CitationClass=journal
}}</ref> and research is ongoing to determine whether it could be a viable substitute drug in human cocaine addicts.